Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents
- PMID: 38214375
- DOI: 10.1111/myc.13683
Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents
Abstract
A growing body of literature has marked the emergence and spread of antifungal resistance among species of Trichophyton, the most prevalent cause of toenail and fingernail onychomycosis in the United States and Europe. We review published data on rates of oral antifungal resistance among Trichophyton species; causes of antifungal resistance and methods to counteract it; and in vitro data on the role of topical antifungals in the treatment of onychomycosis. Antifungal resistance among species of Trichophyton against terbinafine and itraconazole-the two most common oral treatments for onychomycosis and other superficial fungal infections caused by dermatophytes-has been detected around the globe. Fungal adaptations, patient characteristics (e.g., immunocompromised status; drug-drug interactions), and empirical diagnostic and treatment patterns may contribute to reduced antifungal efficacy and the development of antifungal resistance. Antifungal stewardship efforts aim to ensure proper antifungal use to limit antifungal resistance and improve clinical outcomes. In the treatment of onychomycosis, critical aspects of antifungal stewardship include proper identification of the fungal infection prior to initiation of treatment and improvements in physician and patient education. Topical ciclopirox, efinaconazole and tavaborole, delivered either alone or in combination with oral antifungals, have demonstrated efficacy in vitro against susceptible and/or resistant isolates of Trichophyton species, with low potential for development of antifungal resistance. Additional real-world long-term data are needed to monitor global rates of antifungal resistance and assess the efficacy of oral and topical antifungals, alone or in combination, in counteracting antifungal resistance in the treatment of onychomycosis.
Keywords: antifungal agents; antimicrobial stewardship; dermatophytes; drug resistance; fungal.
© 2024 The Authors. Mycoses published by Wiley-VCH GmbH.
Similar articles
-
Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.Antimicrob Agents Chemother. 2013 Apr;57(4):1610-6. doi: 10.1128/AAC.02056-12. Epub 2013 Jan 14. Antimicrob Agents Chemother. 2013. PMID: 23318803 Free PMC article.
-
Efinaconazole 10% and Tavaborole 5% Penetrate Across Poly-ureaurethane 16%: Results of In Vitro Release Testing and Clinical Implications of Onychodystrophy in Onychomycosis.J Drugs Dermatol. 2016 Sep 1;15(9):1116-20. J Drugs Dermatol. 2016. PMID: 27602975
-
In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes.Med Mycol. 2006 Jun;44(4):357-62. doi: 10.1080/13693780500536893. Med Mycol. 2006. PMID: 16772230
-
Antifungal resistance in superficial mycoses.J Dermatolog Treat. 2022 Jun;33(4):1888-1895. doi: 10.1080/09546634.2021.1942421. Epub 2021 Jun 30. J Dermatolog Treat. 2022. PMID: 34132155 Review.
-
Management of toenail onychomycosis.Am J Health Syst Pharm. 1999 May 1;56(9):865-71. doi: 10.1093/ajhp/56.9.865. Am J Health Syst Pharm. 1999. PMID: 10344609 Review.
Cited by
-
Pediatric Nail Disorders.Skin Appendage Disord. 2024 Oct;10(5):342-356. doi: 10.1159/000538835. Epub 2024 May 22. Skin Appendage Disord. 2024. PMID: 39386306 Review.
-
Treatment of Onychomycosis and the Drug-Drug Interactions in Patients with Diabetes Mellitus and Diabetic Foot Syndrome: A Systematic Review.Infect Dis Rep. 2025 Jan 9;17(1):4. doi: 10.3390/idr17010004. Infect Dis Rep. 2025. PMID: 39846707 Free PMC article. Review.
-
Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.RSC Adv. 2025 Mar 11;15(10):7799-7825. doi: 10.1039/d5ra00387c. eCollection 2025 Mar 6. RSC Adv. 2025. PMID: 40070389 Free PMC article. Review.
-
Application of Platelet-Rich Fibrin and Concentrated Growth Factors as Carriers for Antifungal Drugs-In Vitro Study.J Clin Med. 2025 Jul 18;14(14):5111. doi: 10.3390/jcm14145111. J Clin Med. 2025. PMID: 40725803 Free PMC article.
-
[Dermatomycoses: topical and systemic antifungal treatment].Dermatologie (Heidelb). 2024 Aug;75(8):655-673. doi: 10.1007/s00105-024-05359-y. Epub 2024 Jun 14. Dermatologie (Heidelb). 2024. PMID: 38874607 Review. German.
References
REFERENCES
-
- Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35(5):497-519.
-
- Vlahovic TC, Joseph WS, Scher RK, et al. Diagnosis and management of onychomycosis perspectives from a joint podiatric medicine-dermatology roundtable. J Am Podiatr Med Assoc. 2016;106(2):155-162.
-
- Lipner SR, Scher RK. Onychomycosis: treatment and prevention of recurrence. J Am Acad Dermatol. 2019;80(4):853-867.
-
- Hay RJ. The spread of resistant tinea and the ingredients of a perfect storm. Dermatology. 2022;238(1):80-81.
-
- Miller RA. A case for antifungal stewardship. Curr Fungal Infect Rep. 2018;12:33-43.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources